IPROVE launches roadmap to bolster vaccine innovation
17 March 2016 | By Victoria White
IPROVE has launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years...
List view / Grid view
News
Cellectis and MabQuest to develop new class of anti-PD-1 mAbs
17 March 2016 | By Victoria White
These anti-PD-1 mAbs have potential uses for multiple indications in immunotherapy, including notably treatments for a variety of cancers...
Interview with Michael Springer, Associate Professor of Systems Biology, Harvard Medical School
17 March 2016 | By Caroline Richards
Caroline Richards, Editor of Drug Target Review, invites Michael Springer, Associate Professor of Systems Biology, Harvard Medical School to discuss a laboratory study of a yeast model using microfluidic systems...
Amping antimicrobial discovery with high-throughput screening
16 March 2016 | By Victoria White
Researchers from NIST have shown that high-throughput screening can dramatically speed up the challenging task of antimicrobial discovery...
Inovio and Wistar team up for DNA-based immunotherapies
16 March 2016 | By Victoria White
Inovio and the Wistar Institute are to research preventive and therapeutic DNA-based immunotherapies for cancers and infectious diseases...
Sanofi and DiCE Molecules enter research collaboration
16 March 2016 | By Victoria White
Sanofi and DiCE Molecules have entered a five-year global collaboration to discover potential new therapeutics for up to 12 targets...
Johnson & Johnson Innovation launches JLINX
16 March 2016 | By Victoria White
JLINX is designed to catalyse scientific innovations by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem...
SRI International awarded $19.8m to develop cancer preventive vaccines
15 March 2016 | By Victoria White
A division of SRI International will conduct preclinical studies to assess the efficacy of compounds or vaccines for preventing invasive-cancer development...
Blueprint Medicines to develop novel therapeutics targeting immunokinases
15 March 2016 | By Victoria White
Under a collaboration with Roche, Blueprint Medicines will lead preclinical research and development through to Phase I proof of concept...
Researchers identify when Parkinson’s proteins become toxic
15 March 2016 | By Victoria White
Their work could help unravel how and why people develop Parkinson’s, and aid in the search for potential treatments...
Takeda and Frazier Healthcare Partners launch Outpost Medicine
15 March 2016 | By Victoria White
Outpost Medicine is a biopharmaceutical company focused on the development of new treatments of urologic and gynaecologic diseases and disorders...
HRX9 shows promise as a treatment for mesothelioma
14 March 2016 | By Victoria White
After three weeks' treatment with HXR9, human mesothelioma tumours in mice stopped growing, with a complete loss of tumour blood vessels and widespread cancer cell death...
Dr David B. Weiner joins Inovio’s Board of Directors
14 March 2016 | By Victoria White
Dr Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX later became Inovio Pharmaceuticals...
CEGX closes $21 million Series B financing and appoints CEO
14 March 2016 | By Victoria White
Cambridge Epigenetix (CEGX), a pioneer in the development of epigenetic sequencing technologies, has appointed Dr Geoff Smith as CEO...
A step towards the male contraceptive pill
13 March 2016 | By Victoria White
A group of researchers has taken a step toward a male contraceptive pill by tweaking some experimental compounds that show promise...